Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2006-07-27
2009-12-08
Balasubramanian, Venkataraman (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C514S221000, C514S282000, C514S286000, C514S299000, C546S255000, C546S268100, C546S269100, C546S269400, C546S269700, C546S304000, C546S314000, C546S323000, C546S329000
Reexamination Certificate
active
07629337
ABSTRACT:
Heterocyclic compounds that bind chemokine receptors and inhibit the binding of their natural ligands are disclosed. The invention compounds are protective against infection by HIV and exert effects characteristic of antagonists to the CXCR4receptor.
REFERENCES:
patent: 5563151 (1996-10-01), Bowles et al.
patent: 5583131 (1996-12-01), Bridger et al.
patent: 5698546 (1997-12-01), Bridger et al.
patent: 5817807 (1998-10-01), Bridger et al.
patent: 0 434 385 (1991-06-01), None
patent: WO-99/04794 (1999-02-01), None
patent: WO-99/32100 (1999-07-01), None
Kawahara et al., Nucleic Acids Symposium Series (1999), 42(Twentysixth Symposium on Nucleic Acids Chemistry, 1999), 157-158.
Baggiolini et al., Immunology Today (2000) 21(9):418-420.
Biard-Piechaczyk et al., “Role of CXCR4 in HIV-1-induced Apoptosis of Cells with a CD4+, CXCR4+ Phenotype” Immunology Letters (1999) 70:1-3.
Blanco et al., “The CXCR4 Antagonist AMD3100 Efficiently Inhibits Cell-Surface-Expressed Human Immunodeficiency Virus Type 1 Envelop-Induced Apoptosis” American Society for Microbiology (2000), pp. 51-56.
Carroll et al. Science (1997) 276:273-276.
Casella et al., Inorganic Chem. (1996) 35:7516-7525.
Donzella et al., Nature Medicine (1998) 4:72-77.
Fedyk et al., “Maturation Decreases Responsiveness of Human Bone Marrow B Lineage Cells to Stromal-Derived Factor 1 (SDF-1)”, Journal of Leukocyic Biology, 66:667-673, 1999.
Ghosh et al., Inorganic Chem. (1998) 37:6597-6605.
Gultneh et al., Inorganic Chem. (1995) 34:3633-3645.
Gupta et al., J. Biol Chem (1998) 7:4282-4287.
Herbein et al., “Apoptosis of CD8+ T cells is Mediated by Macrophages Through Interaction of HIV gp 120 with Chemokine Receptor CXCR4” Nature (1998) 395:189-193.
Hesselgesser et al., “CD4-Independent Association Between HIV-1 gp 120 and CXCR4: Functional Chemokine Receptors are Expressed in Human Neurons”, Current Biology (1997) 7(2):112-121.
Hesselgesser et al., “Neuronal Apoptosis Induced by HIV-1 Gp 120 and the Chemokine SDF-1a is Mediated by the Chemokine Receptor CXCR4” Current Biology (1998) 8 (10):595-598.
Kanda et al., Angew Chem. Int. Ed. Engl. (1995) 34:588-590.
Kedzierska et al., Antivir. Chem. Chemother. (2001) 12(3):133-150.
Lee et al., “Coreceptor/Chemokine Receptor Expression on Human Hematopoietic Cells: Biological Implications for Human Immunodeficiency Virus-Type 1 Infection” Blood (1999) 93(4):1145-1156.
Miedema et al., Immune. Rev. (1994) 140:35-72.
Nikolic et al., “The p35/Cdk5 Kinase Is a Neuron-Specific Rac Effector That Inhibits Pak1 Activity”, Nature (1998) 395:194.
Ohagen et al., “Apoptosis Induced by Infection of Primary Brain Cultures with Diverse Human Immunodeficiency Virus Type 1 Isolates: Evidence for a Role of the Envelop” Journal of Virology (1999) 73(2):897-906.
Peled et al., Science (1998) 283:845-848.
Ponath, Exp. Opin. Invest. Drugs (1998) 7:1-18.
Schols et al., J. Exp. Med. (1997) 186:1383-1388.
Schols et al., Antiviral Research (1997) 35:147-156.
Schramm et al., “Viral Entry through CXCR4 Is a Pathogenic Factor and Therapeutic Target in Human Immunodeficiency Virus Type 1 Disease”, Journal of Virology (2000) 184-192.
Tachibana et al., Nature (1998) 393:591-594.
Wyatt et al., Science (1998) 280:1884-1888.
Baggiolini, Nature (1998) 392:565-568.
Sehgal et al., Rapid Communication (1998) 99-104.
Eitner et al., Transplantation (1998) 66:1551-1557.
R&D Systems, Inc. Fluorokine product insert, Dec. 15, 2003.
Capralogics product insert, www.capralogics.com/CIO117.htm, visited Mar. 23, 2005.
Atsma Bem
Bogucki David
Bridger Gary J.
Crawford Jason
Harwig Curtis
Balasubramanian Venkataraman
Genzyme Corporation
Morrison & Foerster / LLP
LandOfFree
Chemokine receptor binding heterocyclic compounds does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Chemokine receptor binding heterocyclic compounds, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Chemokine receptor binding heterocyclic compounds will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4135693